Paris, September 2nd, 2019 – 6.00PM CET - Pixium Vision (FR0011950641 - PIX), a bioelectronic company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, announces the evolution of its share capital. The number of voting rights and shares composing its share capital as at August 31st, 2019 is as follow:

Total voting rights Total number of shares composing capital
 

Total real voting rights (1):

 

22,540,446

 
22,606,060 (3)

 
 

Total theoretical voting rights (2):

 

22,606,060

 

(1): The actual (or net) voting rights correspond to the total number of voting rights exercisable at General Meetings. They are calculated based on the total number of voting rights attached to the total number of shares, less any shares without voting rights (treasury shares, etc.).

(2): Theoretical (or gross) voting rights include all voting rights attached to the shares (including those without voting rights).

(3): Including 665,000 new shares in accordance with the contract of Equity Line financing concluded with Kepler Cheuvreux on December 21, 2018


Contacts

Pixium Vision
Chief Financial Officer
Didier Laurens
investors@pixium-vision.com

+33 1 76 21 47 68
Media Relations

LifeSci Advisors
Sophie Baumont
sophie@lifesciadvisors.com
+33 6 27 74 74 49
Investor Relations
LifeSci Advisors
Chris Maggos
chris@lifesciadvisors.com
+41 79 367 62 54

 

For more information, please visit:  www.pixium-vision.com;
And follow us on: @PixiumVision;  www.facebook.com/pixiumvision

               www.linkedin.com/company/pixium-vision

Pixium Vision is listed on Euronext Paris (Compartment C). Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.   Pixium Vision is included in the Euronext CAC All Shares index   Euronext ticker: PIX - ISIN: FR0011950641 – Reuters: PIX.PA – Bloomberg: PIX:FP

 

Attachment